Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar border

Malaria Journal

Volumn 9, Issue 1, 2010, Pages

  Takeuchi, Rie ^a   Lawpoolsri, Saranath ^a   Imwong, Mallika ^a   Kobayashi, Jun ^b   Kaewkungwal, Jaranit ^a   Pukrittayakamee, Sasithon ^a   Puangsa Art, Supalap ^a   Thanyavanich, Nipon ^a   Maneeboonyang, Wanchai ^a   Day, Nicholas Pj ^a   Singhasivanon, Pratap ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; PRIMAQUINE; ANTIMALARIAL AGENT;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIRECTLY OBSERVED THERAPY; DISEASE DURATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SELF ADMINISTRATION; FEMALE; FEVER; FOLLOW UP; GENOTYPE; HUMAN; INFECTION RISK; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALARIA; MALE; MIXED INFECTION; MYANMAR; PATIENT COMPLIANCE; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; REINFECTION; SCHOOL CHILD; THAILAND; PLASMODIUM VIVAX MALARIA; RECURRENT DISEASE; TREATMENT OUTCOME;

ADOLESCENT; ANTIMALARIALS; CHILD; CHILD, PRESCHOOL; CHLOROQUINE; DIRECTLY OBSERVED THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALARIA, VIVAX; MALE; MYANMAR; PRIMAQUINE; RECURRENCE; THAILAND; TREATMENT OUTCOME;

EID: 77958595486     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-9-308     Document Type: Article

References (35)

1. The neglected burden of Plasmodium vivax malaria. K Mendis BJ Sina P Marchesini R Carter, Am J Trop Med Hyg 2001 64 97 106 11425182
2. World Malaria Report 2008. World Health Organization, http://www.who.int/malaria/publications/atoz/9789241563697/en/index.html Accessed 09/05, 2009
3. WHO SEARO, Malaria situation in SEAR countries. World Health Organization, http://www.searo.who.int/EN/Section10/Section21/Section340-4027. htm Accessed 09/05, 2009
4. World Health Organization, Guidelines for the treatment of malaria 2006. 2006
5. Chloroquine sensitivity of Plasmodium vivax in Thailand. S Looareesuwan P Wilairatana S Krudsood S Treeprasertsuk P Singhasivanon V Bussaratid W Chokjindachai P Viriyavejakul K Chalermrut DS Walsh NJ White, Ann Trop Med Parasitol 1999 93 225 230 10.1080/00034989958474 10562823
6. Treatment of vivax malaria on the western border of Thailand. C Luxemburger M van Vugt S Jonathan R McGready S Looareesuwan NJ White F Nosten, Trans R Soc Trop Med Hyg 1999 93 433 438 10.1016/S0035-9203(99)90149-9 10674098
7. Sensitivity of Plasmodium vivax to chloroquine in Sa Kaeo Province, Thailand. K Congpuong K Na-Bangchang K Thimasarn U Tasanor WH Wernsdorfer, Acta Trop 2002 83 117 121 10.1016/S0001-706X(02)00090-6 12088852 (Pubitemid 34671158)
8. Assessment of therapeutic efficacy of chloroquine for vivax malaria in Thailand. S Vijaykadga C Rojanawatsirivej K Congpoung P Willairatana W Satimai C Uaekowitchai B Pumborplub S Sittimongkol A Pinyorattanachote P Prigchoo, Southeast Asian J Trop Med Public Health 2004 35 566 569 15689067
9. Long-term efficacy of primaquine in the treatment of vivax malaria in nonimmune travelers. T Jelinek HD Nothdurft F Von Sonnenburg T Loscher, Am J Trop Med Hyg 1995 52 322 324 7741169
10. Plasmodium vivax infections in U.S. army troops: failure of primaquine to prevent relapse in studies from Somalia. BL Smoak RF DeFraites AJ Magill KC Kain B Wellde, Am J Trop Med Hyg 1997 56 231 234 9080885
11. A relapsed case of imported tertian malaria after a standard course of hydroxychloroquine and primaquine therapy. KJ Yi MH Chung HS Kim CS Kim SH Pai, Korean J Parasitol 1998 36 143 146 10.3347/kjp.1998.36.2.143 9637832
12. Short report: a consideration of primaquine dose adjustment for radical cure of Plasmodium vivax malaria. E Schwartz G Regev-Yochay D Kurnik, Am J Trop Med Hyg 2000 62 393 395 11037784
13. Malaria in the Australian Defence Force during and after participation in the International Force in East Timor (INTERFET). SJ Kitchener AM Auliff KH Rieckmann, Med J Aust 2000 173 583 585 11379495
14. Association of subtherapeutic dosages of a standard drug regimen with failures in preventing relapses of vivax malaria. EC Duarte LW Pang LC Ribeiro CJF Fontes, Am J Trop Med Hyg 2001 65 471 476 11716100
15. Diagnostic and therapeutic pitfalls associated with primaquine-tolerant Plasmodium vivax. JM Spudick LS Garcia DM Graham DA Haake, J Clin Microbiol 2005 43 978 981 10.1128/JCM.43.2.978-981.2005 15695723
16. Clinical trial of oral artesunate with or without high-dose primaquine for the treatment of vivax malaria in Thailand. U Silachamroon S Krudsood S Treeprasertsuk P Wilairatana K Chalearmrult HY Mint P Maneekan NJ White VR Gourdeuk GM Brittenham S Looareesuwan, Am J Trop Med Hyg 2003 69 14 18 12932090
17. Therapeutic responses to antimalarial and antibacterial drugs in vivax malaria. S Pukrittayakamee M Imwong S Looareesuwan NJ White, Acta Trop 2004 89 351 356 10.1016/j.actatropica.2003.10.012 14744561
18. Effects of different antimalarial drugs on gametocyte carriage in P. vivax malaria. S Pukrittayakamee M Imwong P Singhasivanon K Stepniewska NJ Day NJ White, Am J Trop Med Hyg 2008 79 378 384 18784229
19. Relapse/reinfection patterns of Plasmodium vivax infection: A four year study. RN Prasad KJ Virk VP Sharma, Southeast Asian J Trop Med Public Health 1991 22 499 503 1820634
20. Studies on Plasmodium vivax relapse pattern in Kheda district, Gujarat. HC Srivastava SK Sharma RM Bhatt VP Sharma, Indian J Malariol 1996 33 173 179 9125831
21. World Health Organization, Global tuberculosis control: surveillance, planning, financing: WHO report 2006. http://www.who.int/tb/publications/global- report/2006/en/index.html Accessed 10/08, 2009
22. Glucose-6-phosphate dehydrogenase (G6PD) mutations in Thailand: G6PD Viangchan (871G > A) is the most common deficiency variant in the Thai population. I Nuchprayoon S Sanpavat S Nuchprayoon, Hum Mutat 2002 19 185 190 10.1002/humu.9010 11793482
23. Effect of primaquine standard dose (15 mg/day for 14 days) in the treatment of vivax malaria patients in Thailand. K Buchachart S Krudsood P Singhasivanon S Treeprasertsuk N Phophak S Srivilairit K Chalermrut Y Rattanapong L Supeeranuntha P Wilairatana G Brittenham S Looareesuwan, Southeast Asian J Trop Med Public Health 2001 32 720 726 12041544
24. Glucose-6-phosphate dehydrogenase mutations in Mon and Burmese of southern Myanmar. I Nuchprayoon C Louicharoen W Charoenvej, J Hum Genet 2008 53 48 54 10.1007/s10038-007-0217-3 18046504
25. Practical PCR genotyping protocols for Plasmodium vivax using Pvcs and Pvmsp1. M Imwong S Pukrittayakamee AC Gruner L Renia F Letourneur S Looareesuwan NJ White G Snounou, Malar J 2005 4 20 32 10.1186/1475-2875-4-20 15854233
26. Polymorphism at the merozoite surface protein-3 locus of Plasmodium vivax: Global and local diversity. MC Bruce MR Galinski JW Barnwell G Snounou KP Day, Am J Trop Med Hyg 1999 61 518 525 10548283
27. Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. M Imwong G Snounou S Pukrittayakamee N Tanomsing JR Kim A Nandy JP Guthmann F Nosten J Carlton S Looareesuwan S Nair D Sudimack NP Day TJ Anderson NJ White, J Infect Dis 2007 195 927 932 10.1086/512241 17330781
28. In vitro culture of exoerythrocytic parasites of the North Korean strain of Plasmodium vivax in hepatoma cells. MR Hollingdale WE Collins C Campbell, Am J Trop Med Hyg 1986 5 275 276
29. Prepatent periods of a tropical strain of Plasmodium vivax after inoculations of tenfold dilutions of sporozoites. E Ungureanu R Killick-Kendrick PCC Garnham P Branzei C Romanescu PG Shute, Trans R Soc Trop Med Hyg 1976 70 482 483 10.1016/0035-9203(76)90133-4 320727
30. Conversion of dihydroorotate to orotate in parasitic protozoa. WE Gutteridge D Dave WHG Richards, Biochim Biophys Acta 1979 582 390 401 217438
31. Short communication: Why are primaquine and other 8-aminoquinolines particularly effective against the mature gametocytes and the hypnozoites of malaria? DC Warhurst, Ann Trop Med Parasitol 1984 78 165 6378110
32. Observations on early and late post-sporozoite tissue stages in primate malaria. II. The hypnozoite of Plasmodium cynomolgi bastianellii from 3 to 105 days after infection, and detection of 36-to 40-hour pre-erythrocytic forms. WA Krotoski RS Bray PC Garnham RW Gwadz R Killick-Kendrick CC Draper GA Targett DM Krotoski MW Guy LC Koontz FB Cogswell, Am J Trop Med Hyg 1982 31 211 225 7041663
33. Demonstration of hypnozoites in sporozoite-transmitted Plasmodium vivax infection. WA Krotoski WE Collins RS Bray PC Garnham FB Cogswell RW Gwadz R Killick-Kendrick R Wolf R Sinden LC Koontz PS Stanfill, Am J Trop Med Hyg 1982 31 1291 1293 6816080
34. Observations on early and late post-sporozoite tissue stages in primate malaria. IV. Pre-erythrocytic schizonts and/or hypnozoites of Chesson and North Korean strains of Plasmodium vivax in the chimpanzee. WA Krotoski PC Garnham FB Cogswell WE Collins RS Bray RW Gwasz R Killick-Kendrick RH Wolf R Sinden M Hollingdale, Am J Trop Med Hyg 1986 35 263 274 3513645
35. Comparative genomics of the neglected human malaria parasite Plasmodium vivax. JM Carlton JH Adams JC Silva SL Bidwell H Lorenzi E Caler J Crabtree SV Angiuoli EF Merino P Amedeo Q Cheng RM Coulson BS Crabb HA Del Portillo K Essien TV Feldblyum C Fernandez-Becerra PR Gilson AH Gueye X Guo S Kang'a TW Kooij M Korsinczky EV Meyer V Nene I Paulsen O White SA Ralph Q Ren TJ Sargeant SL Salzberg CJ Stoeckert SA Sullivan MM Yamamoto SL Hoffman JR Wortman MJ Gardner MR Galinski JW Barnwell CM Fraser-Liggett, Nature 2008 455 757 763 10.1038/nature07327 18843361